Dramatic response to osimertinib combined with crizotinib in EGFR T790M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer

A case report

Dapeng Li, MD, Qi Gui, MD, Caihua Xu, MD, Meng Shen, MMeD, Kai Chen, MD

Abstract

Rationale: Besides the T790M mutation, it may coexist with bypass pathway activation in real clinical cases for patients with EGFR mutations who resisted to the first- and second-generation tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). There are limited clinical trial data describing the efficacy of osimertinib combined with MET inhibition in EGFR T790M-mutant NSCLC patients with Met amplification.

Patient concerns: A non-smoking 53-year-old male patient with lung adenocarcinoma underwent gefitinib, afatinib, and osimertinib combined with crizotinib treatment and developed different EGFR resistance mutations.

Diagnoses: The patient was diagnosed with lung adenocarcinoma (stage cT4N2M0, IIIB). After resistance to the therapy targeting EGFR exon 21 L858R point mutation, T790M mutation was detected in liquid biopsy and Met amplification was detected via tissue biopsy by next-generation sequencing (NGS).

Interventions: The patient received systemic treatments, including chemotherapy, gefitinib, afatinib, and osimertinib combined with crizotinib.

Outcomes: The patient died of multisystem organ failure and had an overall survival of 24 months.

Lessons: Although osimertinib combined with crizotinib therapy showed dramatic tumor shrinkage in both the primary tumor and bone metastasis to an EGFR T790M-mutant NSCLC patient with MET amplification, the progression-free survival (PFS) was only two months.

Abbreviations: CTCAE = common terminology criteria for adverse events, NGS = next-generation sequencing, NSCLC = non-small cell lung cancer, PET = positron emission tomography, PR = partial response, RECIST = Respond evaluation criteria in solid tumors, TKIs = tyrosine kinase inhibitors.

Keywords: EGFR mutation, MET amplification, next-generation sequencing, NSCLC, tyrosine kinase inhibitor
1. Introduction

Advanced non-small cell lung cancer with EGFR gene mutations is closely related to the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), but the outcomes are limited by acquired resistance.[1] The EGFR exon 20 T790M mutation accounts for 50% to 60% of the resistance to first- and second-generation TKIs, followed by bypass pathway activation (e.g., MET or ERBB2 amplification, mutations in BRAF and PIK3CA), and lineage shifts (e.g., small-cell transformation, epithelial-to-mesenchymal transition).[2,3] ‘Third-generation’ EGFR TKIs, such as osimertinib, are highly effective in EGFR-mutant NSCLC patients harboring the EGFR T790M mutation. Nevertheless, resistance to third-generation EGFR TKIs can still develop through further mutations in EGFR and the activation of alternative pathways.[4]

With the development of high-throughput NGS-based liquid biopsy technology, additional mechanisms, such as EGFR exon 20 C797S, EGFR L718Q, and EGFR exon 18 G724S mutations were observed.[4,5] NGS-based liquid biopsy testing overcomes spatial heterogeneity and can dynamically monitor tumor genomic evolution and guide decision-making for treatment strategies in a minimally invasive manner.[6]

Here, we present the case of an EGFR-mutant advanced NSCLC patient who acquired resistance to first- and second-generation TKIs in a short time. There were different results of the NGS tests between blood samples and tumor tissue samples at the same time, that is, EGFR T790M mutation was only found in blood and Met amplification was only found in tumor tissue. Although there are limited clinical trial data describing the efficacy of osimertinib combined with MET inhibition in patients with EGFR T790M-mutant NSCLC, outcomes in a real-world setting are useful to inform clinical practice. Despite disease progression after only 3 months, the patient experienced substantial symptomatic improvement and dramatic tumor regression following osimertinib combined with crizotinib therapy.

2. Case presentation

In June 2017, an Asian man aged 53 years presented with productive cough. His past medical history included no history of smoking, minimal exposure to secondhand smoke, and no significant comorbidities. Chest CT revealed a left lung lesion in the upper lobe, with metastases in the left hilar and mediastinal lymph nodes (Fig. 1A), which was confirmed by a subsequent PET scan. Transbronchial biopsy confirmed left lung adenocarcinoma (stage cT4N2M0, IIIB). The biopsy tissue was also sent for NGS testing. However, the NGS process lasted a long time in China at that time, and the report came more than one month later. The patient could not accept that he should wait for a long time without any treatment after being diagnosed with lung cancer. Therefore, he received chemotherapy during the waiting period. He initiated six cycles of cisplatin/pemetrexed chemotherapy (pemetrexed 500mg/m², day 1 plus cisplatin 75mg/m², day 1, every 3 weeks) before genotyping results from July 1, 2017 and had a good response on the first evaluation of September 21, 2017. According to RECIST (version 1.1), he reached PR. During this period, NGS testing revealed that the tumor was an EGFR exon 21 L858R point mutation, with an abundance of 8.68%.

Although chemotherapy was effective, the patient declined further chemotherapy because of progressive fatigue and loss of appetite (grade 3 in CTCAE, version 5.0) during chemotherapy. From November 28, 2017 (Fig. 1B), the patient was treated with second-line targeted therapy without disease progression, the first-generation EGFR-TKI gefitinib, at a 250mg standard daily dose. Poor news was found in April 2018. Computed tomography (CT) showed enlargement of the left upper lobe mass, and the patient experienced disease progression (Fig. 1C).

The tumor in the left lobe was small and isolated in lung tissue, which was behind the back ribs and scapula, so it was difficult to obtain tissue biopsy via either percutaneous lung puncture biopsy or transbronchial biopsy. Therefore, liquid biopsy was conducted, and the results showed an EGFR exon 21 L858R point mutation, but the abundance declined to 6.8% and negative for the T790M mutation. The patient was treated with second-generation EGFR-TKI afatinib as the third line in May 2018. Only one month later, the mass in the left lobe had progressed (Fig. 1D). Based on the previous effective response to chemotherapy, he received two cycles of cisplatin and pemetrexed (doses were the same as before) during June and July 2018. Chest CT at the end of July 2018 revealed disease stability. Afterwards, bevacizumab, which is a vascular endothelial growth factor inhibitor, was added to combine with cisplatin and pemetrexed chemotherapy for another two cycles from July to August 2018. Unfortunately, a slightly enlarged left lobe mass and left sixth rib bone metastasis were found on chest CT in September 2018 (Fig. 1E). The patient complained of severe chest pain, fatigue, and loss of appetite.

To further identify the potential therapeutic targets, a biopsy was performed on the left lung mass on September 25, 2018 (confirming adenocarcinoma). Immunohistochemistry staining showed high expression of Ki-67 (80%) and PD-L1 (80%) of tumor cells. Concurrently, NGS testing of both tumor tissue and blood specimens again identified EGFR exon 21 L858R point mutation, and EGFR T790M mutation was only found in blood specimens and Met amplification was only found in tumor tissue specimens. Although highly expression of PD-L1, the role of immunotherapy in patients with EGFR-mutated NSCLC remains controversial.[7] And there are several small samples of clinical trial data describing the efficacy of EGFR-TKIs combined with MET inhibition in EGFR-mutant cancers with acquired resistance to Met amplification.[8,9] Therefore, a decision was made to proceed with the third-generation EGFR-TKI osimertinib (80mg, QD) combined with the MET inhibitor crizotinib (250mg, BID) from October 17, 2018. The patient still experienced fatigue and loss of appetite during this time, but the symptoms of cough and chest pain were substantially alleviated. CT scans performed in November and December 2018 revealed dramatic tumor reduction and achieved a partial response (Fig. 1F).

This PR response did not last, and the lung tumor mass had progressed in January 2019 (Fig. 1G). After the multidisciplinary committee, the patient underwent radiofrequency ablation of the left lung mass and received zoledronic acid for bone metastasis. Subsequently, there was evidence of new widespread disease in the brain at the end of April 2019 (Fig. 1H), and he also received whole-brain radiotherapy. In May 2019, NGS from blood again showed that EGFR L858R, T790M/C797S (cis), and MET L1195V mutations. Currently, there are no targeted therapies against T790M/C797S available in the clinic, and the patient received palliative care. Eventually, the patient died of multisystem organ failure in June 2019.

3. Discussion

The most common acquired resistance mechanism against the first- and second-generation TKIs in EGFR-mutant NSCLC
Figure 1. The profile of treatments, images and NGS results of the patient. (A) Initial Chemotherapy of cisplatin/pemetrexed had a good response to tumor but caused intolerable adverse reactions. The first NGS suggested EGFR 21 L858R mutation. (B) The PFS of first-generation EGFR-TKI gefitinib was only 5 months. (C) The second NGS suggested there was no T790M mutation. And the second-generation EGFR-TKI afatinib was ineffective. (D) The PFS of secondary chemotherapy and plus Bevacizumab was only 4 months. (E) The third NGS suggested EGFR T790M mutation was only in blood and Met amplification was only in tumor tissue. Osimertinib combined with crizotinib showed dramatic tumor shrinkage. (F) The PFS of osimertinib combined with crizotinib was only 3 months. (G) Palliative care for 4 months. (H) Brain metastasis and the fourth NGS of EGFR L858R, T790M/C797S (cis), and MET L1195V mutations.
patients might be the T790M mutation, and other resistant subclones may also coexist in these patients. Amplification of the MET proto-oncogene accounts for 5–20% of acquired resistance to EGFR TKIs. [9] Strong expression of c-Met is associated with poor prognosis of NSCLCs. [10] In this case, we analyzed the potential resistance to EGFR mutations during sequential use of the first- and second-generation TKIs (gefitinib and afatinib) in an advanced lung cancer patient. EGFR T790M was detected in plasma, and MET amplification was found in the tumor at the time of resistance to afatinib. Previous studies have shown that co-occurring genomic events are detected in up to 93% of EGFR-mutant NSCLCs. [11] Tumor biopsies have a greater depth of molecular characterization; however, they may be spatially limited to a minute fragment of patients’ overall cancer burden. The ctDNA comes from multiple disease sites and may illustrate coexistent subclones; thus, liquid biopsies might provide different information about tumor heterogeneity.

MET amplification can drive human epidermal growth factor receptor 3 (ERBB3)-dependent PI3K activation; therefore, it may be involved in EGFR-TKI resistance. [12] Preclinical studies have demonstrated that in EGFR T790M-mutant NSCLCs, aberrant c-Met activity can confer resistance to third-generation EGFR TKIs. [13] This suggests that inhibition of both c-Met and EGFR T790M is effective in preventing the growth of EGFR T790M-mutant NSCLCs with c-Met amplification. A recent case report showed that combinational treatment with a first/third-generation EGFR-TKI and crizotinib resulted in partial responses in two patients with newly acquired MET amplification after osimertinib resistance. [14] Moreover, in a phase I/II trial of capmatinib (a small-molecule MET receptor TKI) combined with gefitinib in EGFR-mutated tumors after EGFR inhibitor treatment failed NSCLC, the ORR was 47% in patients with MET gene copy number (GCN) ≥ 6 subgroup. [15] In the TATTON study, the objective response rate was 44% in the group treated with osimertinib combined with savolitinib (MET-TKI). [16] Our case confirmed these observations and revealed that EGFR T790M mutation and MET amplification in different samples can clinically document coexistent, genetically distinct subpopulations differentially responding as predicted by their genotype in real time to therapies. Although the progression-free survival (PFS) of osimertinib in combination with crizotinib was only 3 months, the patient experienced substantial symptomatic improvement in chest pain and achieved partial responses.

Further liquid biopsy provided insight into clonal dynamics after treatment failure with osimertinib combined with crizotinib, emergence T790M/C797S. A previous study reported that the EGFR exon 20 C797S mutation was a major resistance mechanism to osimertinib. [17] C797S may disrupt the key EGFR exon 20 C797S mutation was a major resistance and overall survival. Repeated NGS testing during treatment may provide insight into clonal evolution and help to select the optimal drugs to achieve better overall clinical outcomes.

Author contributions

Conceptualization: Dapeng Li, Qi Gui, Kai Chen.

Data curation: Caihua Xu.

Resources: Meng Shen.

Supervision: Kai Chen.

Writing – original draft: Dapeng Li, Qi Gui.

References

[1] Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Engl J Med 2005;352:786–92.

[2] Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.

[3] Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240–7.

[4] Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689–99.

[5] Bersanelli M, Minari R, Bordi P, et al. L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. J Thorac Oncol 2016;11:121–3.

[6] Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 2016;7:11815.

[7] Soo RA, Lim SM, Syn NL, et al. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: current controversies and future directions. Lung Cancer 2018;115:12–20.

[8] Della Corte CM, Ciaramella V, Cardone C, et al. Antitumor efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NCLC tumor models. J Thorac Oncol 2018;13:810–20.

[9] Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol 2019;12:63.

[10] Blackley CM, Watkins TKB, Wu W, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 2017;49:1693–704.

[11] Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479–88.

[12] Nanjo S, Yamada T, Nishihara H, et al. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS One 2013;8:e84700.

[13] Engelmann JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039–43.
[14] Wang Y, Li L, Han R, Jiao L, Zheng J, He Y. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. Lung Cancer 2018;118:105–10.

[15] Wu YL, Zhang L, Kim DW, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol 2018;36:3101–9.

[16] Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol 2020;31:507–16.

[17] Song HN, Jung KS, Yoo KH, et al. Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer. J Thorac Oncol 2016;11:e45–7.

[18] Wang S, Song Y, Liu D. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett 2017;385:51–4.

[19] Han JJ, Kim DW, Koh J, et al. Change in PD-L1 expression after acquiring resistance to gefitinib in EGFR-mutant non-small-cell lung cancer. Clin Lung Cancer 2016;17:263–70. e2.

[20] Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 2017;28:1532–9.

[21] Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol 2017;12:403–7.

[22] Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378:2288–301.